CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P

临床试验：四价人 P 的 II 期安全性和免疫原性研究

• 批准号: 7950822
• 负责人: Sharon A Nachman
• 金额: $ 0.21万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950822
• 关键词: Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Human; Human Papillomavirus; Human papillomavirus 6; Institution; Laboratory Research; Phase; Placebos; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Vaccines; Virus-like particle; immunogenicity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the safety and effect of an investigational vaccine against human papilloma virus (HPV). The investigational vaccine is called Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle [VLP] Vaccine (QHPV Vaccine, also known as GARDASIL¿¿). Both the vaccine and placebo used in this study will be provided by Merck Research Laboratories. The study will look at two things.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究是为了评估一种针对人乳头瘤病毒（HPV）的研究性疫苗的安全性和有效性。 研究疫苗被称为人乳头瘤病毒（6、11、16、18型）L1病毒样颗粒[VLP]疫苗（QHPV疫苗，也称为GARDASIL疫苗）。 本研究中使用的疫苗和安慰剂均由Merck Research Laboratories提供。 这项研究将关注两件事。